Initial Statement of Beneficial Ownership (3)
06 Julio 2020 - 4:23PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BRISTOL MYERS SQUIBB CO |
2. Date of Event Requiring Statement (MM/DD/YYYY)
11/20/2019
|
3. Issuer Name and Ticker or Trading Symbol
ACCELERON PHARMA INC [XLRN]
|
(Last)
(First)
(Middle)
430 E. 29TH STREET, 14 FLOOR |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
NEW YORK, NY 10016
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 6971772 | I | See Explanation of Responses (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | These shares are owned directly by Celgene Corporation ("Celgene"). On November 20, 2019, Bristol-Myers Squibb Company ("BMS") completed the acquisition of 100% of the issued and outstanding share capital of Celgene pursuant to a Merger Agreement under the laws of Delaware. Upon the completion of the Celgene acquisition, Celgene became a wholly owned subsidiary of BMS. BMS is an indirect beneficial owner of the reported securities. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
BRISTOL MYERS SQUIBB CO 430 E. 29TH STREET 14 FLOOR NEW YORK, NY 10016 |
| X |
|
|
Signatures
|
/s/ Katherine Kelly, Secretary of Bristol-Myers Squibb Company | | 7/6/2020 |
**Signature of Reporting Person | Date |
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc Artículos de Noticias